

Success through personalized FVIII treatment



Wednesday
2nd February, 2022
18:00–19:00 CET

EAHAD Satellite Symposium **Organized and sponsored by Bayer**



Agenda

18:00–18:15 CET Introduction and opening remarks

Setting the scene for achieving new heights in Hemophilia A treatment

Johannes Oldenburg

18:15–18:30 CET Expanding Hemophilia A treatment based on new clinical findings

An overview of Jivi® (damoctocog alfa pegol) from PROTECT VIII to real

world evidence (HEM-POWR)

Mark Reding

18:30–18:40 CET Importance of meeting our individual patient's needs

Highlighting the effectiveness of Jivi® (damoctocog alfa pegol)

in managing difficult cases

Dario di Minno

18:40–18:50 CET What do we expect from gene therapy in Hemophilia A treatment?

Safety, efficacy, durability and eligibility: establishing goals for gene therapy

Hermann Eichler

18:50–19:00 CET Q&A panel

Johannes Oldenburg